Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
Abstract Background 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therapy. The use of generators containing less than 222 MBq 225Ac (actinium), due to limited av...
Saved in:
Main Authors: | Ho Sze Chan (Author), Erik de Blois (Author), Mark W. Konijnenberg (Author), Alfred Morgenstern (Author), Frank Bruchertseifer (Author), Jeffrey P. Norenberg (Author), Fred J. Verzijlbergen (Author), Marion de Jong (Author), Wouter A. P. Breeman (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2016-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic Performance Evaluation of <sup>213</sup>Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([<sup>213</sup>Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology
by: Zita Képes, et al.
Published: (2023) -
A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling
by: Stanislav Ermolaev, et al.
Published: (2021) -
First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
by: Maryana Handula, et al.
Published: (2023) -
Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals
by: Erik de Blois, et al.
Published: (2019) -
L'égalité des dotations initiales
by: MATHELIER, Guillaume
Published: (2020)